Phospho-CDKN1C (T310) Antibody

What is CDKN1C and what role does it play in cell cycle regulation?

CDKN1C (also known as p57Kip2) belongs to the CIP/KIP family of cyclin-dependent kinase inhibitors (CKIs) that regulate cell cycle progression. CDKN1C functions primarily as a negative regulator of cell proliferation by binding to and inhibiting various cyclin/CDK complexes, particularly those involved in G1 phase progression.

CDKN1C contains an N-terminal cyclin-dependent kinase inhibitor (CDI) domain, a central proline-alanine (PAPA) repeat region, and a C-terminal region with a proliferating cell nuclear antigen (PCNA) binding motif and a nuclear localization signal . Like other CIP/KIP family members (p21CIP and p27KIP1), CDKN1C plays crucial roles in coordinating cell cycle arrest, differentiation, and development .

What is the significance of phosphorylation at threonine 310 (T310) in CDKN1C?

Phosphorylation at threonine 310 (T310) represents a critical post-translational modification that influences CDKN1C function, localization, and stability. This specific phosphorylation site is located in the C-terminal region of the protein, near the putative nuclear localization signal .

Similar to phosphorylation patterns observed in related CKI family members, T310 phosphorylation likely affects CDKN1C's ability to bind to cyclin/CDK complexes and may regulate its subcellular localization between the nucleus and cytoplasm. Phosphorylation events in CKIs often create binding sites for regulatory proteins such as 14-3-3 or components of the ubiquitin-proteasome system, potentially influencing protein stability and turnover .

How do I select the appropriate Phospho-CDKN1C (T310) Antibody for my experiment?

When selecting a Phospho-CDKN1C (T310) antibody, consider these methodological criteria:

• Validation status: Choose antibodies validated specifically for your application (WB, IHC, IF, ELISA, etc.) with published data demonstrating specificity .

• Specificity: Verify the antibody recognizes only phosphorylated T310 and not unphosphorylated CDKN1C or other phosphorylation sites. Review data showing the antibody's specificity through phosphatase treatments or mutant controls .

• Species reactivity: Confirm reactivity with your experimental species. Many Phospho-CDKN1C antibodies are validated for human samples, with variable cross-reactivity to mouse or rat samples .

• Clonality: Consider whether monoclonal (consistent production but single epitope) or polyclonal (variation between lots but multiple epitopes) better suits your needs .

• Format compatibility: Ensure the antibody is compatible with your detection system (unconjugated, fluorophore-labeled, etc.) .

What are the optimal sample preparation techniques for Phospho-CDKN1C (T310) detection?

For optimal phospho-protein detection, follow these methodological considerations:

• Rapid sample processing: Process samples quickly to preserve phosphorylation status, as phosphatases remain active during cell lysis.

• Phosphatase inhibitors: Include a comprehensive phosphatase inhibitor cocktail in all buffers (sodium fluoride, sodium orthovanadate, sodium pyrophosphate, β-glycerophosphate) to maintain phosphorylation .

• Lysis buffer optimization: Use RIPA or NP-40 based buffers supplemented with protease inhibitors for most applications.

• Sample handling: Maintain samples at 4°C throughout processing and avoid repeated freeze-thaw cycles.

• Protein quantification: Perform accurate protein quantification before loading to ensure comparable results.

• Denaturing conditions: Use appropriate SDS-PAGE sample buffer with reducing agents to fully denature the protein and expose the phospho-epitope .

• Positive controls: Include samples treated with phosphatase activators and inhibitors to validate antibody specificity.

How should I optimize Western blot protocols for Phospho-CDKN1C (T310) detection?

Western blot optimization for phospho-specific antibodies requires several methodological considerations:

• Gel percentage: Use 12-15% polyacrylamide gels for optimal resolution of CDKN1C (~57 kDa).

• Transfer conditions: Optimize semi-dry or wet transfer conditions for efficient transfer of phosphorylated proteins (typically 100V for 60-90 minutes or 30V overnight).

• Blocking optimization: Test both BSA and milk-based blocking solutions; note that milk contains phosphatases that may reduce signal for some phospho-epitopes.

• Antibody dilution: Begin with the manufacturer's recommended dilution range (1:500-1:2000) and optimize as needed .

• Incubation conditions: Extend primary antibody incubation to overnight at 4°C for improved sensitivity.

• Detection system: Use enhanced chemiluminescence or fluorescence-based detection with appropriate sensitivity for your expected signal strength.

• Stripping and reprobing: If assessing both phosphorylated and total CDKN1C, consider running duplicate gels rather than stripping, as stripping can remove phospho-epitopes.

What controls should be included when using Phospho-CDKN1C (T310) Antibody?

Rigorous experimental design requires appropriate controls:

• Positive control: Include lysates from cells known to express phosphorylated CDKN1C at T310 (estrogen-stimulated breast cancer cell lines may be suitable) .

• Negative control: Use CDKN1C-knockout cells or tissues, or samples treated with lambda phosphatase to remove phosphorylation.

• Loading control: Include detection of housekeeping proteins (β-actin, GAPDH) to ensure equal protein loading.

• Total CDKN1C control: Run parallel blots or samples with antibodies detecting total CDKN1C regardless of phosphorylation status to normalize phospho-signal to total protein levels.

• Peptide competition: Pre-incubate antibody with phospho-peptide immunogen to demonstrate binding specificity.

• Treatment controls: Include samples from cells treated with kinase activators or inhibitors that affect the signaling pathways regulating CDKN1C phosphorylation.

How does T310 phosphorylation relate to other post-translational modifications of CDKN1C?

CDKN1C undergoes multiple post-translational modifications that function in concert to regulate its activity. Understanding these interactions requires integrating information across experiments:

• Phosphorylation network: Similar to p27KIP1, CDKN1C likely has a complex phosphorylation profile, with T310 phosphorylation potentially interacting with other phosphorylation events. In p27KIP1, phosphorylation at multiple sites (including T157, T198, S10) affects localization, stability, and CDK binding .

• Modification crosstalk: Phosphorylation may influence or be influenced by other modifications such as ubiquitination (affecting protein degradation) or acetylation (observed in p27KIP1 at K100, affecting stability) .

• Isoform-specific modifications: Consider that different CDKN1C isoforms (316aa isoform A, 305aa isoform B, 131aa isoform D) may exhibit distinct phosphorylation patterns and functional outcomes .

• Temporal dynamics: Modifications likely occur in specific sequences, with certain phosphorylation events serving as priming sites for subsequent modifications, as observed with T187 phosphorylation in p27KIP1 leading to SCF-mediated degradation .

• Subcellular localization effects: Phosphorylation may drive nuclear-cytoplasmic shuttling of CDKN1C, similar to how S10, T157, and T198 phosphorylation affects p27KIP1 localization .

What is the relationship between estrogen signaling and CDKN1C T310 phosphorylation?

Evidence suggests complex regulation of CDKN1C by estrogen signaling through multiple mechanisms:

• Transcriptional suppression: Estrogen reduces CDKN1C expression approximately 3-fold through epigenetic mechanisms involving the chromatin-interacting noncoding RNA KCNQ1OT1 and CCCTC-binding factor (CTCF) .

• Chromatin remodeling: Estrogen activation leads to increased recruitment of CTCF to both the distal KCNQ1OT1 promoter-associated imprinting control region and the CDKN1C locus, establishing repressive histone modifications .

• Phosphorylation regulation: While direct evidence for estrogen's effect on T310 phosphorylation is limited, estrogen is known to activate kinase cascades (including Akt, ERK1/2) that phosphorylate related CKI family members. These pathways may similarly target T310 in CDKN1C .

• Antisense regulation: Estrogen signaling induces a cis-encoded antisense transcript, CDKN1C-AS, following pharmacologic inhibition of DNA methyltransferase and histone deacetylase activity. Forced expression of CDKN1C-AS can repress endogenous CDKN1C, potentially affecting phosphorylation patterns .

• Cell cycle implications: Given that CDKN1C phosphorylation status affects cell cycle progression, estrogen's promotion of cell proliferation may involve modulation of T310 phosphorylation to inactivate CDKN1C's growth inhibitory functions.

How can phosphoproteomics approaches complement Phospho-CDKN1C (T310) Antibody studies?

Integrating targeted antibody-based approaches with global phosphoproteomics offers several advantages:

• Comprehensive phosphorylation profiling: Mass spectrometry-based phosphoproteomics can identify all phosphorylation sites on CDKN1C simultaneously, revealing potential interactions between T310 phosphorylation and other modification sites.

• Quantitative dynamics: Stable isotope labeling approaches (SILAC, TMT, iTRAQ) enable precise quantification of phosphorylation changes across different conditions or time points.

• Pathway context: Phosphoproteomics provides information on the broader signaling network in which CDKN1C functions, revealing upstream kinases and downstream effectors.

• Low-abundance detection: Enrichment strategies (phospho-peptide enrichment via IMAC, TiO2, or phospho-specific antibodies) can capture low-abundance CDKN1C phospho-peptides that might be missed in targeted approaches.

• Novel site discovery: Unbiased phosphoproteomics may reveal previously uncharacterized phosphorylation sites on CDKN1C that functionally interact with T310 phosphorylation.

• Confirmation workflow: Results from phosphoproteomics experiments can be validated using Phospho-CDKN1C (T310) antibody in orthogonal techniques (Western blot, immunofluorescence).

How can I distinguish between CDKN1C isoforms when using phospho-specific antibodies?

Differentiating between CDKN1C isoforms requires careful experimental design:

• Isoform expression analysis: Begin with qRT-PCR using isoform-specific primers to determine which CDKN1C transcripts are expressed in your experimental system. The ENSEMBL database contains several CDKN1C transcripts encoding different isoforms (CDKN1C-202 encodes 316aa isoform A, CDKN1C-204 encodes 305aa isoform B, CDKN1C-201 encodes 131aa isoform D) .

• Molecular weight discrimination: Use high-resolution SDS-PAGE (12-15% gels) to separate isoforms based on molecular weight differences (isoform A: ~57 kDa, isoform B: ~55 kDa, isoform D: ~14 kDa).

• Isoform-specific domains: Consider whether T310 is present in all isoforms. Based on the information from search results, T310 is located in the C-terminal region and may not be present in truncated isoforms like isoform D (131aa) .

• Epitope mapping: Perform epitope mapping experiments using recombinant isoforms or domain deletion mutants to confirm antibody specificity.

• Isoform-specific knockdown: Use siRNA targeting specific exons to selectively deplete individual isoforms and observe changes in Phospho-CDKN1C (T310) signal.

What are common pitfalls in interpreting Phospho-CDKN1C (T310) immunoblot results?

Accurate interpretation requires awareness of several technical challenges:

• Cross-reactivity: Phospho-specific antibodies may detect similar phospho-epitopes in related proteins (p21CIP, p27KIP1). Verify using knockout controls or peptide competition assays .

• Dephosphorylation during processing: Inadequate phosphatase inhibition during sample preparation can lead to false-negative results. Ensure rapid processing with appropriate inhibitor cocktails.

• Basal phosphorylation variability: Baseline T310 phosphorylation may vary between cell types or culture conditions, necessitating appropriate normalization.

• Antibody lot variation: Phospho-specific antibody performance can vary between lots. Maintain consistent antibody sources for comparative studies.

• Signal specificity: Confirm that changes in signal represent true phosphorylation changes rather than altered total protein levels by normalizing to total CDKN1C.

• Post-translational modifications masking: Other modifications near T310 might mask the epitope, preventing antibody binding despite presence of phosphorylation.

• Context-dependent phosphorylation: T310 phosphorylation may be cell cycle-dependent or stimulus-specific, requiring precise experimental timing.

How can I optimize immunoprecipitation protocols for studying Phospho-CDKN1C (T310) interactions?

Effective immunoprecipitation of phosphorylated proteins requires specific optimization:

• Antibody selection: For IP applications, choose antibodies specifically validated for immunoprecipitation. Some antibodies work well for Western blot but poorly for IP .

• Lysis conditions: Use mild non-denaturing lysis buffers (NP-40 or Triton X-100 based) to preserve protein-protein interactions while maintaining phospho-epitope integrity.

• Cross-linking strategy: Consider using reversible cross-linking agents to stabilize transient interactions before lysis.

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Bead selection: Test both protein A, protein G, and magnetic beads to determine optimal capture efficiency.

• Washing stringency: Balance between removing non-specific binding (higher stringency) and maintaining specific interactions (lower stringency).

• Elution methods: Compare different elution methods (low pH, SDS, peptide competition) for optimal recovery of phosphorylated complexes.

• Sequential IP: Consider sequential immunoprecipitation to first enrich for total CDKN1C followed by phospho-specific enrichment.

How does CDKN1C T310 phosphorylation status relate to cancer development and progression?

Current research suggests several important connections between CDKN1C phosphorylation and cancer:

• Expression patterns: CDKN1C expression is reduced or lost in the majority of breast cancers, suggesting its function as a tumor suppressor .

• Estrogen response: Estrogen signaling, often dysregulated in hormone-dependent cancers, suppresses CDKN1C through epigenetic mechanisms, which may influence its phosphorylation status .

• Cell cycle dysregulation: As a cell cycle regulator, altered CDKN1C phosphorylation could contribute to the hallmark cancer trait of uncontrolled proliferation.

• Cytoplasmic mislocalization: By analogy with p27KIP1, phosphorylation-induced cytoplasmic mislocalization of CDKN1C may convert its function from tumor suppressive to potentially oncogenic, promoting cell motility and epithelial-mesenchymal transition .

• Imprinting alterations: CDKN1C is an imprinted gene on chromosomal band 11p15.5, and epigenetic mechanisms affecting its expression and regulation are implicated in Beckwith-Wiedemann syndrome and cancer development .

What experimental models are most appropriate for studying CDKN1C T310 phosphorylation dynamics?

Selecting appropriate models requires consideration of biological relevance and technical feasibility:

• Cell line selection:

  • MCF7 cells have been used successfully to study estrogen-mediated regulation of CDKN1C

  • Consider cell lines with documented CDKN1C expression and phosphorylation

  • Compare normal and cancer-derived cells to identify disease-specific changes

• Genetic modification approaches:

  • CRISPR/Cas9 to generate T310 phospho-mutants (T310A to prevent phosphorylation, T310E to mimic phosphorylation)

  • Inducible expression systems for wild-type and mutant CDKN1C

  • siRNA knockdown of specific kinases to identify those responsible for T310 phosphorylation

• Primary tissue models:

  • Patient-derived xenografts with varying CDKN1C status

  • Primary cell cultures with intact signaling networks

  • Organoid models to maintain tissue architecture and cell-cell interactions

• In vivo models:

  • Transgenic mouse models with CDKN1C mutations

  • Patient-derived xenografts

  • Developmental models (given CDKN1C's role in development)

• Disease-specific contexts:

  • Models of Beckwith-Wiedemann syndrome to study CDKN1C dysregulation

  • Hormone-responsive and hormone-resistant cancer models to assess estrogen effects

How might T310 phosphorylation affect CDKN1C's interaction with noncoding RNAs and epigenetic regulators?

Emerging research suggests complex interplay between phosphorylation states and epigenetic regulation:

• Chromatin interaction dynamics: Phosphorylation may alter CDKN1C's ability to interact with chromatin or chromatin-modifying complexes, similar to how other phosphorylated proteins show modified DNA binding capabilities.

• KCNQ1OT1 interaction: Research has shown that CDKN1C expression is regulated by the chromatin-interacting noncoding RNA KCNQ1OT1. Phosphorylation at T310 might modulate this interaction, potentially affecting the recruitment of epigenetic modifiers .

• CTCF-mediated regulation: CTCF has been implicated in CDKN1C regulation, with estrogen increasing CTCF recruitment to both the KCNQ1OT1 promoter and CDKN1C locus. Phosphorylation could affect CTCF binding or function at these sites .

• CDKN1C-AS modulation: The cis-encoded antisense transcript CDKN1C-AS can repress endogenous CDKN1C. Phosphorylation might influence how CDKN1C interacts with this antisense transcript or affects its processing .

• Nuclear vs. cytoplasmic functions: Phosphorylation-dependent localization changes could determine which pool of noncoding RNAs CDKN1C interacts with, as nuclear and cytoplasmic RNA populations differ significantly.